A decade on, the evidence is in: what biosimilar treatment means for patients

EURACTIV - A decade after the first biosimilar reached European patients with rheumatoid arthritis, the evidence is in: patients do as well on the copies as on the original biologics, and a million patient-years of use confirm they are safe. Read more

[Aliaksandr Zadoryn via Getty Images]